Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 59Stomach Neoplasms 12Colonic Neoplasms 9Rectal Neoplasms 5Triple Negative Breast Neoplasms 3Endometrial Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Sarcoma 2Neoplasms 2Neoplasm Metastasis 2NSCLC 2Esophageal Squamous Cell Carcinoma 2Esophageal Neoplasms 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Advanced Solid Tumors 2Advanced Colorectal Carcinoma 2Unresectable Metastatic Colorectal Cancer 1To Evaluate the Efficacy of Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Colorectal Carcinoma 1Squamous Cell Carcinoma of Head and Neck 1Platinum Resistant Ovarian Cancer 1Patients With Advanced Metastatic Colorectal Cancer 1Pancreatic Neoplasms 1Neoplasm, Residual 1Metastatic Gastroesophageal Junction Adenocarcinoma 1Metastatic Colorectal Adenocarcinoma 1Metastasis Colorectal Cancer 1MSS Metastatic Colorectal Cancer 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1

Interventions

Capecitabine 20Oxaliplatin 13Irinotecan 8spartalizumab 6tislelizumab 4Radiation 4Immune Checkpoint Inhibitors 4Fluorouracil 4toripalimab 3Neoadjuvant Therapy 3sintilimab 2camrelizumab 2Radiotherapy 2Leucovorin 2Celecoxib 2veliparib 1peposertib 1nimotuzumab 1irinotecan sucrosofate 1XELOX 1Thymalfasin 1Radiotherapy, Intensity-Modulated 1Injections 1HMPL-013 1Folfox protocol 1Diathermy 1Combined Modality Therapy 1Chemoradiotherapy 1Amifostine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Locally Advanced Rectal Cancer × HMPL-013 × Clear all
NCT04989855 2021-08-04

Fruquintinib Plus PD-1 Antibody in pMMR / MSS Locally Advanced Rectal Cancer (LARC) With High Immune Score

Sun Yat-sen University

Phase 2 Unknown
48 enrolled
Gastrointestinal

Locally Advanced Rectal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡